Investor
Relations
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Investor
Relations
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Upcoming Events
No upcoming events found.
Date:
April 29, 2025
-
April 29, 2025
Annual Shareholders’ Meeting to approve Recordati S.p.A.’s 2024 financial statements and to appoint Board of Directors
Date:
April 29, 2025
-
April 29, 2025
Recordati: 2025-2027 Plan Presentation
Location:
Milan
Date:
May 8, 2025
-
May 8, 2025
Board of Directors’ meeting to approve the 2025 first quarter results, as additional voluntary financial reporting
Revenue trend 2019 - 2023 (million Euro)
Revenue by business unit 2019 - 2023 (million Euro)
Total Revenue split by Therapeutica area - FY 2023
(SPC 63.1%, Rare Disease 34.3%)
Note: Total OTC of € 331.3 million in FY 2023 and € 300.7 million in FY 2022 Subsidiaries’ local product portfolios of € 238.4 million in FY 2023 and € 237.1 million in FY 2022
Pharmaceutical revenue (excluding Chemicals) split by Geographic - FY 2023
Key P&L Data
|
(million Euro)
|
FY 2023
|
|
FY 2022
|
|
FY 2021
|
|
FY 2020
|
|
FY 2019
|
|---|---|---|---|---|---|---|---|---|---|
(million Euro)
Revenue
|
FY 2023
2,082.3
|
FY 2022
1,853.3
|
FY 2021
1,580.1
|
FY 2020
1,448.9
|
FY 2019
1,481.8
|
||||
(million Euro)
Gross Profit
as % of revenue |
FY 2023
1,422.6
68.3 |
FY 2022
1,286.6
69.4 |
FY 2021
1,152.3
72.9 |
FY 2020
1,042.0
71.9 |
FY 2019
1,044.9
70.5 |
||||
(million Euro)
Adjusted Gross Profit (1)
as % of revenue |
FY 2023
1,481.6
71.1 |
FY 2022
1,336.4
72.1 |
FY 2021
1,152.3
72.9 |
FY 2020
1,042.0
71.9 |
FY 2019
1,044.9
70.5 |
||||
(million Euro)
Operating Income (EBIT)
as % of revenue |
FY 2023
558.0
26.8 |
FY 2022
437.3
23.6 |
FY 2021
490.2
31.0 |
FY 2020
469.0
32.4 |
FY 2019
465.3
31.4 |
||||
(million Euro)
Adjusted Operating Income (Adj. EBIT) (2)
as % of revenue |
FY 2023
626.6
30.1 |
FY 2022
536.1
28.9 |
FY 2021
504.6
31.9 |
FY 2020
469.0
32.4 |
FY 2019
465.3
31.4 |
||||
(million Euro)
Net Income
as % of revenue |
FY 2023
389.2
18.7 |
FY 2022
312.3
16.9 |
FY 2021
386.0
24.4 |
FY 2020
355.0
24.5 |
FY 2019
368.9
24.9 |
||||
(million Euro)
Adjusted Net Income (3)
as % of revenue |
FY 2023
524.6
25.2 |
FY 2022
473.3
25.5 |
FY 2021
424.6
26.9 |
FY 2020
410.4
28.3 |
FY 2019
382.4
25.8 |
||||
(million Euro)
EBITDA (4)
as % of revenue |
FY 2023
769.6
37.0 |
FY 2022
672.8
36.3 |
FY 2021
602.3
38.1 |
FY 2020
569.3
39.3 |
FY 2019
544.0
36.7 |
2) Net income before income taxes, financial income and expenses, non-recurring items, and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3)
3) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3) and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects
4) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3)
Balance Sheet at December 2023 (million Euro)
Net Debt - FY 2021 - 2023 (million Euro)
Net Debt / EBITDA1 - FY 2021 - 2023 (million Euro)
1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS).
*EBITDA pro-forma considering the contribution of Avodart® and Combodart®/Duodart® for the last twelve months (as was stated in the press release / presentation)
